Company Overview and News

Hammer Metals raises $1 million to fast-track exploration programs

Hammer Metals Ltd (ASX:HMX) has raised just over $1 million dollars through a non-renounceable option entitlement offer as well as a strategic share placement.

Hammer Metals identifies copper-gold prospects from high-grade rock chips at Perentie

Hammer Metals Ltd (ASX:HMX) has delineated four copper-gold prospects at its newly-termed Perentie Project in Queensland’s Mount Isa mining district.

Hammer Metals drills best intersection to date at cobalt project

Hammer Metals Ltd (ASX:HMX) has unveiled significant results from the final four holes of its diamond drilling campaign at the Millennium cobalt-copper-gold deposit, near Cloncurry, north-west Queensland.

Cobalt-focused miners eye the perfect storm with demand set to double

There has never been a better time to develop cobalt-focused mining assets with demand for the battery component predicted to double over the next decade.

Cobalt-focused juniors eye the perfect storm with demand set to double

There has never been a better time to develop cobalt-focused mining assets with demand for the battery component predicted to double over the next decade.

Newmont and Hammer to end Mt Isa joint venture

Hammer Metals is to conclude its joint venture (JV) agreement with Newmont Exploration as the latter has decided not to continue exploration funding.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:HMX / HAMMER METALS LIMITED on message board site Silicon Investor.

Phymatrics (PHMX) Phymatrics (PHMX) Phymatrics (PHMX)